LI

Lexicon Pharmaceuticals, Inc.

www.lexpharma.com link_icon

Company Research Report: Lexicon Pharmaceuticals, Inc.



Company Overview



  • Name: Lexicon Pharmaceuticals, Inc.

  • Mission: Pioneering medicines that transform patients' lives.

  • Founded: No information is available.

  • Founders: No information is available.

  • Key People:

  • Mike Exton, Ph.D. - Chief Executive Officer and Director

  • Raymond Debbane - Chairman

  • Brian Corrigan - Senior Vice President, Regulatory and Quality Assurance

  • Lisa DeFrancesco - Vice President, Investor Relations and Corporate Communications

  • Tom Garner - Senior Vice President and Chief Commercial Officer

  • Headquarters: No information is available.

  • Number of Employees: No information is available.

  • Revenue: No information is available.

  • Known For: Lexicon Pharmaceuticals is known for its unique approach to gene science based on Nobel Prize-winning technology. The company focuses on the discovery and development of precise medicines for serious, chronic conditions, especially in the fields of cardiometabolism and neuroscience.


Products



  • INPEFA® (Sotagliflozin)

  • Description: INPEFA is a once-daily oral tablet designed to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults.

  • Key Features:

  • Targets both heart failure and type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

  • Approved by the FDA following Phase 3 cardiovascular outcomes studies (SOLOIST-WHF and SCORED).

  • Demonstrated significant reduction in the risk of hospitalizations and cardiovascular death compared to placebo.

  • Common adverse reactions include urinary tract infection, volume depletion, diarrhea, and hypoglycemia.


Recent Developments



  • Recent Developments:

  • Lexicon Pharmaceuticals has commercialized INPEFA® for heart failure treatment.

  • The FDA approved INPEFA® as of May 26, 2023.

  • New Products Launched:

  • INPEFA® (Sotagliflozin) for heart failure.

  • New Features Added to Existing Products:

  • No information is available.

  • New Partnerships:

  • No information is available.


Pipeline



  • Current Pipeline:

  • INPEFA® (Sotagliflozin) for Heart Failure

  • Target: SGLT2/SGLT1

  • Status: Approved

  • LX9211 for Diabetic Peripheral Neuropathic Pain (DPNP)

  • Target: AAK1

  • Status: Wholly Owned

  • Sotagliflozin for Type 1 Diabetes and Hypertrophic Cardiomyopathy (HCM)

  • Target: SGLT2/SGLT1

  • Status: Wholly Owned


Additional Information



  • Approach: Lexicon applies a unique approach to gene science, establishing a strong pipeline, and exploring new therapeutic areas such as cardiometabolism and neuroscience.

  • Production: The company retains exclusive rights and advantages from certain drug discovery and development programs and intends to capitalize on these through strategic alliances.

  • Investor Information: Managed by Lisa DeFrancesco, Vice President of Investor Relations and Corporate Communications.




This report provides a detailed insight into Lexicon Pharmaceuticals based on the available data. Please note the absence of specific founding details, headquarters location, employee count, and revenue information.